LOX and neoplasm: They proposed that tumour-derived growth factors (VEGF, Lysyl Oxidase) released by disseminated tumour cells (DTCs) act for the purpose of ‘priming’ the bone ECM to facilitate a more favourable microenvironment for DTC attraction, survival and proliferation (Chiou et al., 2021).